Modifiedmedical mutual - ohioPolicy AHS - G2043 - Celiac Disease Testing

Celiac Disease Testing

Clinical coverage policy for laboratory and diagnostic testing related to celiac disease, including indications, testing intervals, allowed and disallowed assays, and confirmatory biopsy guidance for members covered by Medical Mutual - Ohio.

Policy Summary

Payermedical mutual - ohio

PolicyCeliac Disease Testing

Policy CodePolicy AHS - G2043 - Celiac Disease Testing

Change TypeCode removals and literature update

Effective DateFeb 1, 2026

Next Review DateSep 4, 2025

Key ActionDocument serology results (including TGA-IgA level and total IgA) and biopsy site/number when submitting for diagnostic confirmation.

SourceLink

POLICY UPDATE CHANGES

Removed CC7, which referred to genetic testing, as the focus of this policy is routine testing for the diagnosis of celiac disease.

Removed CPT codes 81376, 81377, 81382, 81383 from the policy code list.

Updated the background, guidelines and recommendations, and evidence-based scientific references without modifying coverage criteria.

4+recommended distal duodenal biopsies plus 1 bulb biopsy

IgA tTGpreferred initial serologic test

reservedHLA testing use

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CPT/HCPCS codes listed

1%worldwide prevalence quoted

Coverage Criteria for Celiac Disease Testing

Post-diagnosis serologic surveillance

Covered when ALL of the following are met

IgA-sufficient diagnosed patients surveillance: For individuals diagnosed with celiac disease who are IgA sufficient, serologic testing with IgA anti-tissue transglutaminase (TTG) is covered at: (a) first follow-up 3–6 months after diagnosis; (b) every 6 months until normalization of anti-TTG levels; (c) every 12–24 months thereafter.clinical intervals

Supports ongoing monitoring of serology

IgA-deficient diagnosed patients surveillance: For individuals diagnosed with celiac disease who are IgA deficient, testing for IgG endomysial antibodies, IgG deamidated gliadin peptide (DGP), or IgG TTG is covered at: (a) first follow-up 3–6 months after diagnosis; (b) every 6 months until normalization of IgG levels; (c) every 12–24 months thereafter.clinical intervals

Alternative serologic monitoring for IgA deficiency

Initial diagnostic testing

Covered when ALL of the following are met

Symptomatic individuals diagnostic testing: Individuals with signs or symptoms of celiac disease (see Note 1) should receive initial serologic testing with IgA anti-TTG plus total serum IgA to assess IgA sufficiency.symptoms per Note 1

Total IgA required to interpret IgA-based assays

At-risk individuals with negative/weak TTG: For individuals at increased risk for celiac disease, when IgA anti-TTG is negative or weakly positive, testing for IgA endomysial antibodies (EMA-IgA) is covered.risk per Note 1

Reflex/confirmatory testing for at-risk patients

IgA-deficient diagnostic testing: For individuals with clinical suspicion of celiac disease who are IgA deficient, testing for IgG EMA, IgG DGP, or IgG TTG is covered.

Confirmatory biopsy

Covered when ANY of the following are met

Biopsy for confirmation: Pathological examination of small intestine tissue obtained by biopsy (EGD with duodenal biopsies) is covered for confirmation of celiac disease in individuals at high risk regardless of serology results.high risk

Biopsy remains the confirmatory standard for high-risk individuals

Diagnostic and monitoring coverage criteria

Covered when ALL of the following are met for diagnostic evaluation or monitoring as per specialty guidance

Diagnosis - adults/children

Diagnostic pathways: (EGD + multiple biopsies) OR (pediatric no-biopsy pathway when TGA≥10× ULN + EMA confirmation)

Serology specifics: Measure total serum IgA and TGA-IgA initially; if IgA deficient, use IgG-based tests (DGP-IgG or TTG-IgG); consider EMA-IgA as confirmatory when using a no-biopsy approach.IgA sufficiency/deficiency determines isotype

AGA/ESPGHAN/ACG recommendations

Pre-test diet and repeat testing: Avoid reduction or avoidance of gluten prior to diagnostic testing; if the patient has already started a gluten-free diet, consider reintroduction of gluten (approximately three slices of wheat bread daily for 1–3 months when clinically appropriate) before repeat TG2-IgA testing.

Diagnostic criteria and testing pathways

Testing and diagnostic actions recommended as per cited societies

Initial serologic testing: Measure total serum IgA AND IgA TGA (tTG-IgA) as first-line tests while the patient is consuming a gluten-containing diet.

If IgA deficient, use IgG-based tests (IgG DGP or IgG tTG); do not start a gluten-free diet before testing

When to use EMA or additional serology: Use IgA EMA when IgA tTG is weakly positive OR use IgG EMA/IgG DGP/IgG tTG when IgA deficiency is present; EMA serves as a confirmatory test when biopsy is not performed.

EMA is confirmatory in select pathways

HLA testing indications: Reserve HLA-DQ2/DQ8 testing for diagnostic dilemmas (e.g., discrepancy between serology and histology, patient already on a gluten-free diet) rather than for initial screening; a negative HLA result effectively excludes celiac disease.

HLA testing not routine initial test

Policy coverage confirmation

Coverage criteria unchanged after literature review (details of criteria are located in other sections of the policy not included in this excerpt).

Policy coverage: Coverage criteria remain as previously defined in the policy document; the 09/04/2025 literature review updated background and references but did not modify coverage logic.

Refer to the main coverage sections for detailed AND/OR logic

The policy explicitly identifies several assays and test formats that DO NOT MEET COVERAGE CRITERIA. These include rapid antigen point-of-care anti-TTG tests, panel/multiplex/multi-analyte tests (more than two analytes), and anti-reticulin antibody testing. In addition, testing of stool or saliva samples for evaluation of celiac disease is listed among noncovered methods. Use of these assays may result in denial because they lack sufficient published evidence or are not appropriate for routine diagnostic evaluation.

Professional guidance cited by the policy recommends against mass screening of asymptomatic community populations. The American College of Gastroenterology specifically endorses targeted case-finding in clinical practice and recommends against community-wide screening for celiac disease, reserving testing for those with suggestive symptoms, laboratory findings, or higher-risk status such as first-degree relatives.

The policy states that urine, stool, or saliva measurements are not recommended for clinical practice due to lower test performance compared with blood-based serology. These specimen types for celiac evaluation are listed as not meeting coverage criteria and are discouraged by guideline sources for routine diagnostic use.

The policy removed genetic testing (CC7) from its scope because the document focuses on routine diagnostic testing for celiac disease. Corresponding CPT codes for genetic/HLA testing were also removed in the revision; genetic testing references and specific CPT codes (e.g., 81376, 81377, 81382, 81383) were deleted to reflect this change.

Testing of asymptomatic individuals who are not at increased risk for celiac disease is explicitly stated to NOT MEET COVERAGE CRITERIA. The policy treats screening of low-risk, symptom-free persons as not medically necessary and may result in denial if submitted without medical indication or supporting documentation of risk or symptoms.

Routine small-bowel biopsies to assess mucosal healing in children following initiation of a gluten-free diet are not recommended. The policy follows guidance that re-biopsy should be reserved for selected clinical indications—for example, diagnostic uncertainty or concern for an additional condition—rather than performed routinely for surveillance in pediatric patients.

The policy discourages routine use of broad antibody panels in place of a single tTG-IgA assay for initial testing and does not support rapid point-of-care tTG tests for diagnostic quantification. NASPGHAN and other societies recommend tTG-IgA as the preferred first-line test and advise against substituting it with multiplex panels or rapid point-of-care formats for initial diagnostic evaluation.

Following the most recent literature review and revision, no new not medically necessary (NMN) conditions were introduced into the policy. The update refined background and references but did not modify the existing coverage or NMN determinations.

Coding and Test Thresholds

Applicable CPT/HCPCS procedure codesmixed

No codes listed

Referenced laboratory assays / LDTsmixed

LDTs (no CPT listed)

Laboratory-developed tests for celiac serology noted as CLIA-high complexity; several FDA-cleared test names listed (e.g., Quanta Lite Celiac Screen, Quanta Lite Celiac DGP Screen, Quanta Plex Celiac IgA/IgG, EliA Celikey IgG, FIDIS Celiac, IMMULISA celiac ELISA systems).

Covered/Referenced Procedure CodesCPT

82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each.
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.
86231	Endomysial antibody (EMA), each immunoglobulin (Ig) class.
86255	Fluorescent noninfectious agent antibody; screen, each antibody.
86256	Fluorescent noninfectious agent antibody; titer, each antibody.
86258	Gliadin (deamidated) (DGP) antibody, each immunoglobulin (Ig) class.
86364	Tissue transglutaminase, each immunoglobulin (Ig) class.
88305	Level IV - Surgical pathology, gross and microscopic examination, colon biopsy

TGA-IgA threshold for no-biopsy diagnosis — ≥10× ULN

ThresholdTGA-IgA ≥ 10× ULN (use as criterion for pediatric no-biopsy pathway)

ContextAccepted by ACG and ESPGHAN as the high-titer cutoff supporting consideration of a no-biopsy diagnosis in children

Confirmatory actionWhen TGA-IgA ≥10× ULN, obtain a second blood sample for EMA-IgA confirmation per society guidance

High TG2 level for non-biopsy diagnosis in children — > 10 times ULN

Threshold> 10 times ULN for TG2 (TG2/TG2-IgA) in symptomatic children

Diagnostic pathway

Provider Actions, Documentation, and Prior Authorization

Documentation Required

Coverage requires indication and test selection

Coverage of celiac disease testing requires an appropriate clinical indication and selection of the correct test(s). Serologic testing (including total IgA with IgA TTG as the preferred initial assay) and small‑intestinal biopsy meet coverage criteria when performed for indicated clinical scenarios (see Indications and Limitations). Testing asymptomatic, low‑risk individuals is not covered.

Coverage requires documentation of the clinical indication (symptoms, risk status, or monitoring intent).
Preferred initial serology: total IgA + IgA TTG. If IgA deficient or inconclusive, use IgG‑based assays (IgG DGP, IgG EMA, or IgG TTG).
Small‑intestinal biopsy (multiple duodenal biopsies including bulb and distal duodenum) is required for confirmation in most adults and in many clinical scenarios.
Avoid panel/multiplex/multi‑analyte testing (>2 analytes) for diagnosis — these are not covered.

Prior Authorization

Background and Scope

Celiac disease is an autoimmune disorder triggered by gluten that damages small intestinal villi and impairs nutrient absorption. Clinical presentation varies by age: children often present with failure to thrive and diarrhea, while adults more commonly present with abdominal pain, altered bowel habits, and bloating. Genetic susceptibility (HLA-DQ2/DQ8) increases risk but is not diagnostic on its own; serologic testing and histologic examination remain central to diagnosis and monitoring.

Key Terms and Definitions

Key serologic and genetic terms

TTGTissue transglutaminase (enzyme target of disease-specific autoantibodies)

tTG-IgAIgA antibodies against transglutaminase 2 (preferred first-line serologic test)

EMAAnti-endomysial antibodies (IgA) — used as a confirmatory serologic test, especially in no-biopsy pathways

DGPDeamidated gliadin peptides (anti-DGP antibodies) — useful particularly in IgA-deficient patients and in young children

Note 1 — Symptoms and high-risk conditions

Clinical featuresSigns/symptoms raising suspicion for celiac disease include chronic or intermittent diarrhea, unexplained weight loss, abdominal pain/bloating, recurrent nausea/vomiting, iron/B12/folate deficiency, elevated liver transaminases, dermatitis herpetiformis, type 1 diabetes, infertility/miscarriage, osteoporosis/low bone density

Policy Summary

Payermedical mutual - ohio

PolicyCeliac Disease Testing

Policy CodePolicy AHS - G2043 - Celiac Disease Testing

Change TypeCode removals and literature update

Effective DateFeb 1, 2026

Next Review DateSep 4, 2025

Key ActionDocument serology results (including TGA-IgA level and total IgA) and biopsy site/number when submitting for diagnostic confirmation.

SourceLink

On This Page

Use IgG-based assays when IgA deficient

DGP testing indications: IgA and IgG DGP testing is covered for: (a) children under 2 years with clinical suspicion of celiac disease; and (b) individuals over 2 years as a substitute for anti-TTG testing.age-specific

DGP may be used in young children or as alternative to TTG

1–3 months gluten challenge suggested

AGA best practice advice

Monitoring and follow-up: In children, schedule first follow-up 3–6 months after diagnosis, then every 6 months until TGA normalization, then every 12–24 months; perform follow-up with the same assay and evaluate growth, symptoms, and selected nutritional labs.first visit 3–6 months

ESPGHAN follow-up guidance

When biopsy or additional testing is indicated: Consider (re)biopsy in adults or children with lack of response or relapse despite a gluten-free diet, or when diagnosis is uncertain; reserve HLA-DQ2/DQ8 testing for diagnostic dilemmas where a negative result can help exclude celiac disease.clinical grounds or discordant results

ACG/ESPGHAN guidance

Role of biopsy (adults): Duodenal biopsy is required for diagnosis in most adult patients while on a gluten-containing diet; obtain multiple biopsies (at least four including a duodenal bulb sample).

Serology alone is insufficient for most adults

Children non-biopsy pathway: In symptomatic children with TG2 >10× ULN AND positive EMA AND presence of HLA-DQ2/8, diagnosis may be made without duodenal biopsy; follow-up should include antibody decline and clinical response to a gluten-free diet.TG2 > 10× ULN

Pediatric no-biopsy pathway per ESPGHAN/ACG guidance

When TG2 >10× ULN plus positive EMA and compatible HLA (if used), some guidelines permit diagnosis without duodenal biopsy in children

Follow-upDiagnosis should be confirmed by subsequent antibody decline and preferably clinical response to a gluten-free diet

Prior authorization required for no‑biopsy pediatric diagnosis

Prior authorization is required to support a no‑biopsy diagnosis in pediatric patients. Documentation must demonstrate a TGA‑IgA level ≥10× the laboratory upper limit of normal (ULN) measured on an assay with an appropriate calibrator range, plus a confirmatory positive EMA‑IgA on a second blood sample, and parental/patient agreement to the no‑biopsy approach.

TGA‑IgA ≥10× ULN (assay must report a measurable 10× ULN).
Positive EMA‑IgA on a separate confirmatory blood sample.
Documentation of informed consent/parental agreement for a no‑biopsy diagnosis in children.

Prior Authorization

Prior authorization and listed CPT/HCPCS codes

Some listed CPT/HCPCS procedure codes may require prior authorization per payer administrative rules. Providers should obtain any required authorizations prior to testing or endoscopy and include documentation supporting medical necessity.

Common codes referenced: 82784, 83516, 86231, 86255, 86256, 86258, 86364, 88305.
Obtain prior authorization when local payer policy or benefit plan requires it before performing serology panels or endoscopic biopsy procedures.
Include the clinical indication, serology results, IgA status, and proposed biopsy plan in the authorization request.

Denial Risk

Noncovered tests that may trigger denial

Certain tests and test formats are not covered and may result in claim denial. Rapid point‑of‑care TTG tests, broad multiplex panels (>2 analytes) for celiac diagnosis, and non‑recommended sample types are excluded.

Rapid antigen point‑of‑care anti‑TTG tests — not covered.
Panel, multiplex, or multi‑analyte testing for more than two analytes for diagnosis/evaluation — not covered.
Testing of stool or saliva for celiac disease evaluation — not covered.
Anti‑reticulin antibodies and HLA‑DQ‑gluten tetramer assays — not covered for routine diagnosis.

Note

Avoid gluten restriction before testing / Gluten challenge guidance

Patients should be tested while on a gluten‑containing diet. Providers should counsel patients not to reduce or avoid gluten prior to initial serologic or biopsy testing because this decreases test sensitivity.

Advise patients to eat gluten regularly before testing; NICE recommends >1 meal/day for at least 6 weeks when feasible.
If a patient already started a gluten‑free diet, consider HLA‑DQ2/DQ8 testing and/or a structured gluten challenge prior to repeat serology.
For repeat serology after prior gluten restriction, a gluten challenge of ~3 slices of wheat bread daily for 1–3 months is suggested where clinically appropriate.

Documentation Required

Follow applicable government policies

Coverage determinations must follow applicable government policies (e.g., LCDs, NCDs) when those policies apply to the member. If a conflict exists between this policy and a relevant government coverage determination, the government determination takes precedence.

Verify Medicare LCD/NCDs and state Medicaid policies for the member before relying on this policy.
When government policy is more restrictive or prescriptive, apply the government rule for the specific member.

Documentation Required

Conflict with government policy

When federal or state government coverage (e.g., LCD/NCD for Medicare or state Medicaid rules) conflicts with this policy for a specific member, the government policy will be used to make the coverage determination.

Check CMS and state Medicaid websites for the most up‑to‑date coverage guidance.
Document which government policy was applied when it supersedes this policy.

Documentation Required

Clinical documentation to support testing

Clinical documentation must support the medical necessity of testing. Include presenting signs/symptoms, relevant risk factors, total IgA result, specific serology values (quantitative TTG level with ULN reference), and prior testing or treatments (e.g., gluten‑free diet).

Record the indication (symptoms per Note 1, family history, type 1 diabetes, syndromic risk factors, monitoring after diagnosis).
Include total IgA level and quantitative TTG result with lab reference range/ULN.
If IgA deficient, document use of IgG‑based assays and the reason for selecting them.
For monitoring, document timing relative to diagnosis and prior serology trends.

Documentation Required

Required diagnostic documentation

Required diagnostic documentation should accompany claims for definitive diagnosis or confirmation: serology results (including quantitative TGA‑IgA and total IgA), endoscopic biopsy pathology report specifying sites and number of biopsies (duodenal bulb + multiple distal duodenal biopsies), and notes on histology when applicable.

For adult diagnosis: pathology report showing at least four biopsies from distal duodenum plus at least one duodenal bulb biopsy when biopsy performed.
Include serology performed while on gluten‑containing diet and specify assay values and ULN.
When a no‑biopsy approach is used in children, include TGA‑IgA ≥10× ULN, confirmatory EMA‑IgA on a second sample, and documentation of shared decision‑making.

Billing Rule

Coding and claim submission

Use the procedure codes listed in this policy when submitting claims and ensure supporting documentation is attached. Providers should code accurately for the tests and procedures performed and follow payer billing guidance.

Referenced procedure codes: 82784, 83516, 86231, 86255, 86256, 86258, 86364, 88305.
Ensure pathology (88305) claims specify specimen site (duodenal bulb, distal duodenum) and number of biopsy samples.
Attach serology lab reports showing quantitative results and assay ULN when submitting claims.

Note

Surveillance schedule (informational)

Surveillance and follow‑up testing schedules are informational guidance for monitoring individuals with established celiac disease. For IgA‑sufficient patients, first follow‑up serology is generally at 3–6 months after diagnosis, then every 6 months until normalization, and thereafter every 12–24 months. For IgA‑deficient patients, follow the analogous schedule using IgG‑based assays.

IgA‑sufficient: first follow‑up 3–6 months; every 6 months until TTG normalizes; then every 12–24 months.
IgA‑deficient: first follow‑up 3–6 months using IgG assays; every 6 months until normalization; then every 12–24 months.
Follow‑up biopsy may be considered for lack of clinical response or to assess mucosal healing per guideline recommendations.

Documentation Required

Preferred test sequence

Preferred test sequence: begin with total IgA and IgA TTG as the primary screen. If total IgA is low or the TTG result is inconclusive/discordant, proceed to IgG‑based testing (IgG DGP, IgG EMA, or IgG TTG) as appropriate. EMA is useful as a confirmatory test when TTG is negative/weakly positive in at‑risk individuals.

Initial tests: total serum IgA + IgA TTG.
If IgA deficient: perform IgG DGP, IgG EMA, or IgG TTG.
If TTG is negative or weakly positive in an at‑risk person, consider IgA EMA for confirmation.

High-risk conditionsGenetic syndromes (Down syndrome, Turner syndrome, Williams-Beuren syndrome) and autoimmune conditions (type 1 diabetes) increase pretest probability

Pediatric-specific signsIn children, consider fatty stools, delayed puberty, failure to thrive, stunted growth, short stature

High-titer tissue transglutaminase IgA — TGA-IgA ≥10× ULN

DefinitionHigh-titer TGA-IgA defined as TGA-IgA ≥ 10× upper limit of normal (ULN)

UseRequired threshold for consideration of pediatric no-biopsy diagnostic pathway per ESPGHAN guidance

Assay requirementOnly antibody tests with calibrator curves that include the 10× ULN measurement range should be used for this determination

Endomysial antibody (IgA) used as confirmatory serologic test — EMA-IgA

TestEndomysial antibody (IgA) — EMA-IgA used as a confirmatory serologic test, especially when considering no-biopsy diagnosis in children

RoleA positive EMA-IgA on a second blood sample increases diagnostic certainty and is recommended before omitting biopsy in pediatric pathway

PerformanceEMA is highly specific and used as confirmatory when TG2-IgA is strongly positive or when biopsy is not performed

IgA deficiency — Total IgA insufficient level that invalidates IgA-based serologic testing

Threshold referenceTotal IgA level below which IgA-based tests are invalid — NICE cites <0.07 g/L as a documented threshold for IgA deficiency

ImplicationDocumented IgA deficiency invalidates IgA-based serologic testing and indicates use of IgG-based assays (IgG DGP, IgG tTG, or IgG EMA)

ActionMeasure total serum IgA concurrently with tTG-IgA to determine appropriate isotype testing

Serologic markers — Autoantibodies used for CD detection

Preferred markerIgA tTG (tTG-IgA) — recommended first-line serologic test for suspected celiac disease

Confirmatory markerIgA EMA — used to confirm strong tTG-IgA results, particularly in pediatric no-biopsy pathways

Alternative markersAnti-DGP (DGP-IgG or DGP-IgA) — useful particularly in IgA-deficient patients and children under 2 years

Laboratory-developed test (LDT)

DefinitionLaboratory-developed tests (LDTs) are assays developed and validated in-house by laboratories and are regulated by CMS under CLIA '88 as high-complexity tests

Regulatory noteLDTs are not FDA-approved/cleared but may be used clinically; performing lab should be CLIA-certified

Provider actionProviders should confirm the performing laboratory's CLIA status and validated assay name when relying on LDT results

FDA-cleared/approved celiac assays

ExamplesFDA-cleared/approved celiac assays include Quanta Lite Celiac Screen, Quanta Lite Celiac DGP Screen, Quanta Plex Celiac profiles, EliA Celikey IgG, Bioplex 2200 Celiac kits, and Aptiva Celiac Disease IgA/IgG reagents

Regulatory implicationThese assays have FDA clearance/approval and are available as alternatives to LDTs for clinical testing

DocumentationWhen submitting testing for authorization or claims, specify the assay name and whether it is FDA-cleared or an LDT as applicable